Publication:
Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes.

datacite.rightsopen.access
dc.contributor.authorChimbetete, Cleophas
dc.contributor.authorShamu, Tinei
dc.contributor.authorKeiser, Olivia
dc.date.accessioned2024-10-25T16:41:43Z
dc.date.available2024-10-25T16:41:43Z
dc.date.issued2020-03-02
dc.description.abstractBACKGROUND In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. METHODS We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. RESULTS A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6-3.4), 1.3 (IQR: 0.7-1.7) and 1 (0.6-1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6-2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml. CONCLUSION Our findings demonstrate that, with comprehensive care, patients failing second-line ART can achieve high rates of virological suppression on third-line regimens. There is need to decentralize the provision of third-line ART in Zimbabwe. More needs to be done to improve completeness of data in the government clinics.
dc.description.numberOfPages11
dc.identifier.doi10.48350/183414
dc.identifier.pmid32119663
dc.identifier.publisherDOI10.1371/journal.pone.0228601
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/167841
dc.language.isoen
dc.publisherPublic Library of Science
dc.relation.ispartofPLoS ONE
dc.relation.issn1932-6203
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.relation.schoolDCD5A442C3E5E17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleZimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue3
oaire.citation.startPagee0228601
oaire.citation.volume15
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2023-06-14 08:58:58
unibe.description.ispublishedpub
unibe.eprints.legacyId183414
unibe.journal.abbrevTitlePLOS ONE
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Chimbetete_PLoSOne_2020.pdf
Size:
695.55 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections